Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 27 chart positions in 27 markets.
By chart position
- 🇦🇺AU · Life Sciences#5730K to 100K
- 🇨🇦CA · Life Sciences#6630K to 100K
- 🇬🇧GB · Life Sciences#1425K to 30K
- 🇺🇸US · Life Sciences#1915K to 30K
- 🇩🇪DE · Life Sciences#1915K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
82K to 309K🎙 Weekly cadence·73 episodes·Last published 2mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
164K to 618K🇦🇺16%🇨🇦16%🇳🇬16%+24 more - Active Followers
Loyal subscribers who consistently listen
66K to 247K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Designing a Global Market Access Strategy Built for MFN
Apr 21, 2026
1h 00m 11s
LATAM Market Access Unlocked: Insights from Argentina, Brazil, Colombia, and Mexico
Apr 2, 2026
56m 41s
The Evolving NHS – An ICS Chief Pharmacist’s Perspective
Nov 17, 2025
31m 25s
First to Market: Unlocking Switzerland’s Pharma Potential
Nov 12, 2025
44m 31s
Q&A Webinar: The Evolving NHS Landscape in England – From Policy to Practice
Oct 13, 2025
1h 00m 10s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 4/21/26 |  Designing a Global Market Access Strategy Built for MFN✨ | Most Favored Nation pricingglobal pharmaceutical strategy+4 | — | Centers for Medicare & Medicaid ServiceMFN+3 | — | MFNpharmaceutical strategy+5 | — | 1h 00m 11s | |
| 4/2/26 |  LATAM Market Access Unlocked: Insights from Argentina, Brazil, Colombia, and Mexico | Send us Fan Mail How do LATAM healthcare markets differ and what do these differences mean for Pharma and Medtech launch planning? What should global market access teams know to support affiliates in Argentina, Brazil, Colombia, and Mexico? How do evidence requirements, access routes, and payer expectations vary across the region? For global market access teams planning for launch in Latin America (LATAM), understanding the diversity and complexity of this region is essential. Healthcare sys... | 56m 41s | ||||||
| 11/17/25 |  The Evolving NHS – An ICS Chief Pharmacist’s Perspective | Send us Fan Mail What does the evolving NHS landscape look like through the eyes of a Chief Pharmacist, and how are integrated care system (ICS) pharmacy teams responding? In this Petauri Evidence NHS Whispers session, we put your questions to Yousaf Ahmad (Chief Pharmacist and Director of Medicines Optimisation, Frimley ICS), as he shares how he and his colleagues are responding to the changing NHS environment. From system pressures and financial constraints to prescribing priorities and ser... | 31m 25s | ||||||
| 11/12/25 |  First to Market: Unlocking Switzerland’s Pharma Potential | Send us Fan Mail What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing? This episode explores Switzerland’s potential as an early launch market. In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Acc... | 44m 31s | ||||||
| 10/13/25 |  Q&A Webinar: The Evolving NHS Landscape in England – From Policy to Practice | Send us Fan Mail In this NHS Whispers live Q&A webinar, Katie Mulholland (Senior Consultant, UK Market Access, Petauri Evidence) speaks to: - Sarah Everest Ford (Programme Director, Health and Care Partnership) - Patrick McGee (Deputy Programme Director for Pathology, Lancashire & South Cumbria) - Prof. Phil Richardson (Former Dorset ICS System Commissioning Director; now Chief Innovation Officer, Petauri Evidence) Together, they explore the implications of changing... | 1h 00m 10s | ||||||
| 7/18/25 |  Global Pricing and Market Access – Strategies for Success in an Evolving Landscape | Send us Fan Mail Uncover the forces driving change in global pricing and access In this expert-led discussion we explore the latest trends, challenges, and strategic considerations shaping global pricing and market access (GPMA). At Petauri Evidence, our Global Pricing and Market Access Team are growing to meet the increasing complexity of global launch and access, bringing together fresh perspectives and decades of real-world experience. In this episode, our experts, Clare Foy and Adam Brow... | 52m 41s | ||||||
| 6/3/25 |  Transforming Global Market Access: Smarter Resource Management with Local Affiliates | Send us Fan Mail Discover a smarter way to manage and share market access resources with local affiliates Are your global market access resources scattered, leading to inconsistencies and confusion among your affiliates? In this webinar we discussed how a centralised platform can streamline resource sharing, ensure access to nationally-relevant evidence, and put the resources your local affiliates need right at their fingertips. The webinar features a conversation with Tim Styche (Market Acc... | 33m 52s | ||||||
| 4/29/25 |  Communicating value to US Payers: Insights for Pharma and Medtech | Send us Fan Mail What do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging resonates in the US? How do you prepare for launch in a market as diverse as the US? In this Global Whispers episode, Louise Maddison (Senior Consultant – Global Market Access, Petauri Evidence) interviews some of our colleagues from Petauri Advisors who are either former payers, or former industry market access... | 59m 02s | ||||||
| 4/24/25 |  Navigating market access: Launch strategies and health economic modelling for medical devices | Send us Fan Mail Discover how health economics can support successful Medical Device launch, proposition development, and market access This episode offers an insightful journey into the world of medical device market access. Specialists from our health economics and market access teams explore the hidden challenges faced by medical devices companies when taking new innovations to healthcare leaders, communicating value and demonstrating evidence, and offer tips on leveraging health economic... | 44m 41s | ||||||
| 11/27/24 |  Navigating US payer evidence needs to optimise market access | Send us Fan Mail What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market? In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evid... | 57m 34s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 11/20/24 |  Best practice RWE approaches to support economic modelling for HTA | Send us Fan Mail How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison? Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Access) shares some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data. Josep... | 59m 53s | ||||||
| 11/18/24 |  NHS winter planning 2024–25 – Engaging with NHS decision-makers through Autumn to Christmas | Send us Fan Mail How is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months? In August, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by Jo Turl (Former Director of Commissioning, Devon ICS) to explore these challenges. Jo and Karen discuss: How ICBs and Directors of Commissioning prepare for winter pressuresThe current key ... | 1h 02m 50s | ||||||
| 10/11/24 |  De-mystifying the NHS – What you need to know about the NHS as a market for your health technology | Send us Fan Mail Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a new health technology to the NHS in England? In July 2024, Global Whispers and NHS Whispers came together, to bring you an overarching view of what it takes to access the NHS with a medtech or pharmaceutical innovation. Guest speaker Dr Faris Al-Ramadani who shared his experience of introducing new technol... | 56m 15s | ||||||
| 9/10/24 |  NHS primary care panel – the GP Contract and Operational Planning Guidance | Send us Fan Mail What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the biggest challenges facing primary care in 2024–25? In this webinar, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) spoke to a panel of NHS Associates about the current state and future of primary care and what this means for industry. Our panellists ... | 1h 02m 14s | ||||||
| 8/12/24 |  Engage NHS healthcare decision-makers with RWD | Send us Fan Mail Discover how data visualisation dashboards can aid field teams in market access discussions with customers. Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting decision-makers with RWD within a well-designed, easy-to-use visualisation can build a case for change, while positioning themselves as a trusted partner. Watch this 20-minute discussion between Iain Shield (Associate Director – Market Access) and Ben Spurr (Head of Partnershi... | 20m 55s | ||||||
| 6/20/24 |  Market access and reimbursement in Canada – changes at CADTH | Send us Fan Mail What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The University of Ottawa). We take a look at the market access, health policy, and health technology assessment in Canada. Clare Foy and Don Hus... | 47m 43s | ||||||
| 5/10/24 |  Rare Disease market access in the MENA and Nordic regions | Send us Fan Mail Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region? In this webinar, our Globa... | 59m 10s | ||||||
| 4/9/24 |  How does funding flow in NHSE Regions? | Send us Fan Mail Which decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders? We sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion that explored finance, funding flows, system priorities, and the decision-making process in NHS Regions. Richard heads up system co-ordination w... | 1h 00m 15s | ||||||
| 4/9/24 |  NHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024) | Send us Fan Mail What do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation? Host Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by guest speakers Debbie Morgan (Director of Service Improvement and Transformation, Cambridge Universi... | 1h 02m 06s | ||||||
| 3/22/24 |  De-mystifying health economic model classifications and structures | Send us Fan Mail What is health economic evaluation and which modelling approaches can be used to support market access activities? In this episode, our expert health economists explain the key strengths and limitations of the most common health economic modelling classifications and structures. Here, Hannah Gillies (Consultant – Health Economics) and Daniel MacDonald (Associate Consultant – Health Economics) de-mystify the different approaches to health economic modelling. Our specialists ... | 1h 00m 28s | ||||||
| 3/12/24 |  Evidence strategy for Medical Technologies and Diagnostics | Send us Fan Mail Here, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies. Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) route be appropriate for your product? What will payers, HTA agencies, and other key decision makers be looking for? And how should this informa... | 53m 24s | ||||||
| 2/26/24 |  How to set your Pharma or Medtech product up for success in the US market | Send us Fan Mail How can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice commercialisation strategy for healthcare products launching in the US market. Clare Foy (Director – Global Market Access, Mtech Access) speaks to Janice MacLennan (Pharma and Medtech brand strategist and founder of NMBLR) about how market access, HEOR and commercialisation leads in Pharma and... | 43m 06s | ||||||
| 2/12/24 |  What's happening with specialised commissioning in the NHS? | Send us Fan Mail What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty? Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech Access) to explore specialised commissioning in the NHS and what to expect as we head into 2024. Malcolm Qualie and David Thorne explored: Spec... | 1h 00m 08s | ||||||
| 1/17/24 |  Integrated care in NHS Wales – what can England learn from its neighbour? | Send us Fan Mail What does it take to run a truly patient-centric integrated health system? What does the Welsh journey with integration tell us about the future for England? Paul Mears (CEO, Cwm Taf Morgannwg University Health Board) joins Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) to explore the integrated care model in Wales and the lessons England can take from the Welsh experience. In this NHS Whispers webinar, guest speaker Paul Mears shares his expe... | 56m 24s | ||||||
| 12/18/23 |  Market access in Italy: Reforms at AIFA | Send us Fan Mail Clare Foy (Director – Global Market Access, Mtech Access) speaks to Italian market access expert Prof. Fabrizio Gianfrate (Professor of Health Economics and Outcomes Research [HEOR] and Ex-Payer) about the market access landscape in Italy, particularly regarding changes at the Agenzia Italiana del Farmaco (AIFA). We explore: - The nature of the Italian market and the reimbursement process - Pricing and market access considerations when launching in Italy - What the reforms a... | 43m 36s | ||||||
Showing 25 of 74
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
28 placements across 27 markets.
Chart Positions
28 placements across 27 markets.